English
This article is from Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology , volume 34 . Abstract Background:: Patients with recurrent and metastatic head and neck Squamous Cell Cancer (HNSCC) have poor prognosis with limited treatment options. In view of decimal prognosis, the treatment decision should include quality of life (QOL) issues, cost-effectiveness besides the response rates and survival. Aim:: Present retrospective analysis was conducted to evaluate efficacy (disease-free survival), pharmacoeconomics, and toxicity profile of four (4) different regimens, viz. gefitinib alone, gefitinib with methotrexate, methotrexate alone, or 5-FU with cisplatin. Materials and Methods:: Case records between 2007 September and 2008 September were analyzed, 68 patients were found suitable for analysis. Patients received gefitinib (250 mg/day), methotrexate as 50 mg intramuscular weekly or a combination of the same or 5-FU 750 mg/m2/day for 4 days along with cisplatin 75 mg/m2/day on day 1 in 21-day cycle. Results:: A total of 68 patients received therapy. Fifty-one patients have clinically meaningful response (stable diseas
Sign in with your free account to read, download EPUBs or listen.
Ebook · Palliative chemotherapy in head and neck squamous cell cancer - What is best in Indian population? A time without symptoms, treatment toxicity score based study. · Anuradha, V., Anand, B. B., Suresh, A. V. S., Sinha, Sudha, Babu, S. Chinna, Suresh, K. · Internet Archive